Six-minute walk distance predicted survival

Connective tissue disease-associated interstitial lung disease follows an unpredictable course, so clinicians look for simple bedside measures that flag who is likely to deteriorate. The six-minute walk test is cheap, quick and reflects the combined contribution of lungs, heart, muscles and effort, which is why it is attractive as a prognostic tool. Whether the distance walked genuinely predicts hard outcomes in this specific population, independent of other clinical variables, had not been well established. Answering that determines whether the test earns a place in routine risk assessment.

This was an ambispective cohort study of patients in stable condition with connective tissue disease-associated interstitial lung disease. Six-minute walk distance measured during hospitalisation was used as the index of exercise tolerance. The primary endpoint was all-cause mortality and the secondary endpoint was hospitalisation for pulmonary disease. In total 224 patients were evaluated, with a median age of 66.5 years (IQR 55.0-74.0) and 146 women, and followed for a median of 1.2 years (IQR 0.6-2.3). The analysis identified optimal cut-off distances and estimated hazard ratios after adjusting for clinical confounding factors.

There were 23 deaths and 56 hospitalisations for pulmonary disease during follow-up. Cut-offs of 310 m for mortality and 260 m for respiratory hospitalisation best separated higher- from lower-risk patients, and Kaplan-Meier curves showed lower event rates above those distances (log-rank 16.146, p < 0.001 for mortality; log-rank 9.065, p = 0.003 for hospitalisation). After adjustment, each 10-metre increase in walk distance was associated with a hazard ratio of 0.962 (95% CI 0.927-0.998) for all-cause mortality and 0.968 (95% CI 0.946-0.991) for hospitalisation. Both confidence intervals sit close to 1, so the per-10-metre effect is small and estimated with limited precision.

The result is consistent with a broad pattern across chronic cardiorespiratory conditions in which walking capacity tracks prognosis, and it extends that pattern to a specific rheumatological lung population. Its main limitation is scale: with 23 deaths, adjusted estimates are fragile, and thresholds derived within the same sample tend to look better here than they will elsewhere. The design also cannot say whether improving walk distance improves outcomes, only that a shorter distance marks higher risk. External validation in independent cohorts, and testing whether rehabilitation changes the trajectory, are the obvious next steps.

The general lesson is that functional capacity - what your body can actually do over a few minutes of walking - carries prognostic information that blood tests and imaging do not fully capture. In this clinical group, walking less far marked greater risk even after other clinical factors were accounted for. That is a reason to think of exercise tolerance as a health signal rather than merely a fitness statistic, though the specific distances here belong to a patient population and a clinical setting. Anything about managing interstitial lung disease is a matter for the treating team.